Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Jii Bum, Kim Dong Kwon, Lee Sang Hoon, Kim Kyung Hwan, Choi Su-Jin, Park So Young, Kim Jae Hwan, Hong Min Hee, Cho Byoung Chul, Lim Sun Min
Аннотация
PURPOSE: SKYROCKET is a single-center, single-arm phase II study that evaluated whether the addition of stereotactic body radiotherapy (SBRT) to atezolizumab plus tiragolumab enhances antitumor efficacy in PD-L1-positive non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS: Patients received SBRT to all metastatic sites and subsequently received atezolizumab and tiragolumab every 3 weeks on day 1 of each 21-day cycle with 7 days of completion of SBRT. The primary endpoint was investigator-assessed progression-free survival (PFS) from the start of SBRT. Exploratory endpoints included single-cell RNA sequencing (scRNA-seq) obtained from tumor biopsies at baseline (BL) and on-treatment (OT) and were further characterized as clinical benefit [CB; partial response or stable disease (SD) ≥ 6 months] and non-clinical benefit (NCB; progressive disease or SD < 6 months).
RESULTS: Forty-one patients were enrolled. At a median duration of follow-up of 9.8 months, median PFS at the start of SBRT was 9.3 months [95% confidence interval (CI), 6.0-NR]. No new safety signal was observed. scRNA-seq of paired BL and OT (n = 3) and single-time point (n = 2) revealed that CD8 progenitor-exhausted (TPEX) cells markedly expanded after treatment, with high T-cell immunoreceptor with Ig and ITIM (TIGIT) and PD-1 expression in CD8 TPEX/TEX subsets. CD4 regulatory T cells (Treg) were reduced in the CB group but increased in the NCB group. The CB group showed reduced Treg suppression and NECTIN-TIGIT signaling, whereas NCB maintained proliferative CTLA4high/TIGIThigh Treg supported by ICAM/galectin-CTLA4 pathways.
CONCLUSIONS: SBRT followed by atezolizumab plus tiragolumab showed encouraging clinical activity with manageable safety in PD-L1-positive metastatic NSCLC.
PATIENTS AND METHODS: Patients received SBRT to all metastatic sites and subsequently received atezolizumab and tiragolumab every 3 weeks on day 1 of each 21-day cycle with 7 days of completion of SBRT. The primary endpoint was investigator-assessed progression-free survival (PFS) from the start of SBRT. Exploratory endpoints included single-cell RNA sequencing (scRNA-seq) obtained from tumor biopsies at baseline (BL) and on-treatment (OT) and were further characterized as clinical benefit [CB; partial response or stable disease (SD) ≥ 6 months] and non-clinical benefit (NCB; progressive disease or SD < 6 months).
RESULTS: Forty-one patients were enrolled. At a median duration of follow-up of 9.8 months, median PFS at the start of SBRT was 9.3 months [95% confidence interval (CI), 6.0-NR]. No new safety signal was observed. scRNA-seq of paired BL and OT (n = 3) and single-time point (n = 2) revealed that CD8 progenitor-exhausted (TPEX) cells markedly expanded after treatment, with high T-cell immunoreceptor with Ig and ITIM (TIGIT) and PD-1 expression in CD8 TPEX/TEX subsets. CD4 regulatory T cells (Treg) were reduced in the CB group but increased in the NCB group. The CB group showed reduced Treg suppression and NECTIN-TIGIT signaling, whereas NCB maintained proliferative CTLA4high/TIGIThigh Treg supported by ICAM/galectin-CTLA4 pathways.
CONCLUSIONS: SBRT followed by atezolizumab plus tiragolumab showed encouraging clinical activity with manageable safety in PD-L1-positive metastatic NSCLC.